Xl784 Diabetic Nephropathy

Exelixis Showcases R&D Pipeline At JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference XL784, which has completed a Phase 1 clinical trial and has U.S. with diabetic nephropathy which represents a large and currently underserved market. ... Read Here

2nd Quarter Financial Results & Business Update Conference Call
Submission of XL784, XL880, XL184 and further compounds to GlaxoSmithKline and the timing thereof; and the timing of the initiation of clinical trials and availability of data for XL184 and XL820. Words such ... View Full Source

Exelixis Announces Transaction To Fund Clinical Development
Broadest possible potential for each compound. For XL784, the funds will be used to conduct comprehensive trials in diabetic nephropathy. Summary Terms of the Transaction ... Retrieve Here

Mechanisms Of Hypertension And diabetic nephropathy
Mechanisms of hypertension and diabetic nephropathy Richard J. Roman, Ph DPh.D. Department of Pharmacology ... View This Document

Forward-Looking Statement - Media.corporate-ir.net
Development Pipeline – Unique High Quality Compounds Lead Op DC IND Phase 1 Phase 2 Phase 3 XL119* Biliary Tract XL784 Diabetic Nephropathy XL999 AML, Colon, Myeloma, NSC Lung, Ovary, Renal ... Content Retrieval

EXACT: Evaluating The Effect Of XL784 On Albuminuria In A ...
INTRODUCTION Diabetic Nephropathy n Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) in the Western world and the ... Doc Viewer

FROM THE ANALYST’S COUCH Avoiding Premature Licensing
XL784 Cancer Cancer Diabetic nephropathy Phase II Phase II Phase II US$80 million June 2005 Isis ISIS 301012 Glucagon Receptor Programme Glucocorticoid Receptor Programme Cholesterol Diabetes Diabetes Phase II Preclinical Preclinical US$75 million April 2006 ... Read More

CURRICULUM VITAE Richard J. Roman Billy S. Gutyon ...
CURRICULUM VITAE . Richard J. Roman Billy S. Gutyon Distiguished Professor and Chair . Department of Pharmacology & Toxicology . University of Mississippi Medical Center ... Access Document

PRLog - GSK Declines Option On Exelixisâ S XL784 After Phase ...
GSK declines option on Exelixis’s XL784 after Phase II results diabetic nephropathy. XL784 is a potent inhibitor of the ADAM-10 and MMP-2 metalloprotease enzymes, which play a role in ... Retrieve Content

ATUL SINGH, M.D. - Nephrology.med.wayne.edu
Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy Phase II Trial. Duration of study 12 months Funding: $100,000, funded by Exelixis. Curriculum Vitae Atul Singh, M.D. Page 3 Original Observations in Journals: ... Fetch This Document

ASCO Investor Briefing (060207) - Library.corporate-ir.net
XL784 and XL999 have been out-licensed to Symphony Evolution, Inc. and are subject to a repurchase option.Pursuant to a product development and Phase 2 POC ongoing in diabetic nephropathy ASCO Investor Briefing (060207).ppt ... Read Full Source

Charting Our Own Course - Media.corporate-ir.net
XL999,XL647,XL880, XL784 Uncommon Approach, George Scangos, President & CEO Extraordinary Results Charting Our Own Course. First Annual Exelixis R&D Day December 6, 2005 Uncommon Approaches, Extraordinary Results Extraordinary productivity - 13 compounds in development since 2003 ... Document Retrieval

Diabetic Kidney Disease: Update GKA Master Class Istanbul 2011
Diabetic Kidney Disease: Update. GKA Master Class. Istanbul 2011 . Sheffield Kidney Institute DKD: Diabetic Nephropathy Microvascular (Hyperperfusion/Hyperfiltration) • XL784 DN • Anti-Fibrotics (miscellaneous): – Pirfenidone DN. ... Get Doc